Vol 7, Supplement 4 (December 2018): Translational Lung Cancer Research

Editorial

A novel biomarker protein panel for lung cancer, a promising first step
Camilo Molina-Romero, Edgar Vergara, Oscar Arrieta
Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer
Chen Zhao, Nobuyuki Takahashi, Arun Rajan
Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine
Vincenzo Di Noia, Ettore D’Argento, Sara Pilotto, Miriam Grazia Ferrara, Michele Milella, Giampaolo Tortora, Emilio Bria
Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine?
Elizabeth J. Buss, Tony J. C. Wang
Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?
Brian Ko, Balazs Halmos
DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients’ clinical management and be a therapeutic target?
Giuseppe Lamberti, Chiara Peterle, Francesco Gelsomino
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer
Chiara Lazzari, Vanesa Gregorc, Alessandra Bulotta, Alessia Dottore, Giuseppe Altavilla, Mariacarmela Santarpia
Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients
Waleed Kian, Laila C. Roisman, Nir Peled
Interplay between immune cells in lung cancer: beyond T lymphocytes
Juan-Manuel Hernandez-Martinez, Edgar Vergara, Edgar Montes-Servín, Oscar Arrieta
Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?
Alessandro Inno, Anna Stagno, Stefania Gori
Specific copy number changes as potential predictive markers for adjuvant chemotherapy in non-small cell lung cancer
Mitsuo Sato
The combination strategies will be ready the right first-line choice for squamous lung cancer patients?
Cesare Gridelli, Francesca Casaluce
Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer
Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane
Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?
Jose Luis Perez-Gracia, Miguel F. Sanmamed, Ignacio Melero
Tumor mutational burden as predictive factor of response to immunotherapy
Maria Gonzalez-Cao, Santiago Viteri, Niki Karachaliou, Andres Aguilar, Juan Jose García-Mosquera, Rafael Rosell
Old myths about old patients: the case of non-small cell lung cancer
Joseph A. Pinto, Luis E. Raez
BRMS1 expression in resected lung adenocarcinoma
Domenico Galetta, Pamela Pizzutilo, Vito Longo
Editorial for “Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse”
Michael Fleischhacker, Bernd Schmidt
Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?
Francesca Casaluce, Cesare Gridelli
Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models
Patricia A. Young, Richard J. Pietras
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer
Rebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano
STAT3 cyclic oligonucleotide decoy—a new therapeutic avenue for NSCLC?
Lennard Y. W. Lee, Summaya Mohammad, Thomas Starkey, Siow-Ming Lee
Role of immune checkpoint blockers in patients with EGFR mutation
Jeffrey Ward, Daniel Morgensztern
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold
Surein Arulananda, Paul Mitchell